LAUSR

In this issue of Neurology®, de Bruijn et al.1 report the difference in efficacy between immunotherapy and antiseizure medications (ASMs) in the treatment of seizures secondary to autoimmune encephalitis. Immunotherapy efficacy clearly exceeded that of ASMs in this cohort with anti–leucine-rich glioma-inactivated 1 (LGI1), anti-NMDA receptor (NMDAR), and anti–gamma-aminobutyric acid B receptor (GABABR) encephalitis on a number of fronts: 53% became seizure-free shortly after initiation of immunotherapy compared to 14% with ASMs and time to seizure freedom with immunotherapy was 28 days vs 59 days in those few who became seizure-free with ASMs. Eventually, 89% became seizure-free following immunotherapy, and ASM therapy could eventually be discontinued in nearly all patients.